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A B S T R A C T
Background. For potential transplant recipients with a prior history of renal malignancy, no evidence-based recommendations currently exist with regard to waiting duration on dialysis. We aim to improve decision making by evaluating the impact of waiting duration on the outcomes of kidney cancer patients awaiting renal transplantation. Methods. The United States Renal Data System was used to identify patients with a known cause of end-stage renal disease (ESRD) from 1983 to 2007. Evaluation of overall survival (OS) was performed with Kaplan-Meier estimates and Cox proportional hazards models. Fine-Gray competing risk models were used to assess cancer-specific mortality (CSM) and non-cancerspecific mortality (NCSM). Results. Of 1 374 175 patients with ESRD, 228 984 (16.7%) received transplantation. Transplant recipients with renal malignancy-associated ESRD (RM-ESRD) had longer waiting durations than those with other known causes of ESRD (2.4 versus 1.3 years; P < 0.0001). RM-ESRD patients who had shorter waiting durations (0-2 years) had better OS than those who waited longer (2þ years) (10-year OS 69.0 versus 46.7%, respectively; P < 0.0001), with similar CSM (10-year CSM 10.3 versus 10.2%, respectively; P ¼ 0.883), whereas NCSM was worse for those with longer waiting durations (10-year NCSM 20.7 versus 44.3%, respectively; P < 0.0001). On Cox modeling, the status of RM-ESRD was not a significant predictor (P ¼ 0.07), while longer waiting duration remained significant (P < 0.0001). Conclusion. We found that CSM was not affected by waiting duration, while NCSM significantly improved with shorter wait times. These findings suggest that the OS of potential transplant recipients with RM-ESRD may be improved by reducing waiting duration.
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I N T R O D U C T I O N
It has long been recognized that waiting duration on dialysis is a significant, modifiable risk factor for potential transplant recipients that affects their long-term survival [1] . On one end of the spectrum, end-stage renal disease (ESRD) patients who receive a preemptive transplant to completely avoid hemodialysis experience a significant survival benefit compared with those who initiate hemodialysis [2, 3] . For ESRD patients who initiate hemodialysis, an earlier transplant (0-1 year) results in improved long-term survival outcomes [4, 5] . On the other hand, for potential recipients with a history of prior malignancy, a precautionary waiting period has classically been employed by many centers due to a higher risk of cancer recurrence posttransplantation, which partially stems from immunosuppressants [6] [7] [8] . While local recurrences with a contralateral tumor in the other kidney may be curable by surgery, distant recurrences are largely incurable [9] . For these reasons, most clinical guidelines have suggested a recurrence-free waiting period of as long as 2-5 years for patients with a history of malignancy, with specifics determined by cancer type and stage [10] [11] [12] [13] [14] , while others advocate for a more personalized approach to account for the oncologic risk of remaining on dialysis [13] .
For patients with a prior history of renal malignancy, a 2-year duration has been proposed for those with a history of renal cell carcinoma (RCC) or other renal malignancies [15, 16] . Others have suggested immediate transplant without a waiting duration in those with incidentally noted localized renal masses, owing to their frequently indolent nature [16] . The rate of recurrence of RCC posttransplantation has been previously reported to be between 5 and 27% in transplant registries [17, 18] . Due to the scarcity of available organs, the initiation of earlier transplantation in this population of ESRD patients has largely been avoided due to concerns of worse prognosis [19] . 
Outside of varying expert opinion, there is a paucity of reported evidence supporting the optimal timing of transplant in those ESRD patients with a history of renal malignancy. We aim to improve such decision making in selecting optimal waiting durations for transplantation in these patients. In this study, we utilize a population-based ESRD registry to examine the outcomes of transplant recipients with a prior history of renal malignancy.
M A T E R I A L S A N D M E T H O D S

Data source and study population
Using the United States Renal Data System (USRDS), patients with ESRD were identified from the period 1983 to 2007 [20] . Patient demographics such as primary cause of ESRD, age at diagnosis, sex, race, transplant status, duration until transplant, nature of the allograft (cadaveric versus living) and date of last follow-up were noted. Patients with an unknown cause of ESRD were excluded from the analysis. For transplant waiting durations, an early transplant was defined as a duration of <2 years until first transplant, whereas a late transplant was defined as a duration >2 years. Survival status was available from the Centers for Medicare and Medicaid Services ESRD Death Notification Form, which provided information regarding the cause of death from cancer or other known causes (OKC). Cancer-specific mortality (CSM) refers to death from any type of malignancy, whereas non-cancer-specific mortality (NCSM) refers to death from other causes. Patients with renal malignancy associated with ESRD (RM-ESRD) were compared with those with other known causes of ESRD (OKC-ESRD).
Statistical analysis
Chi-square and Student t-test were used to evaluate demographic differences between RM-ESRD and OKC-ESRD patients. To assess for overall survival (OS), Kaplan-Meier estimates were employed, while a Fine-Gray model was utilized to evaluate cumulative mortality over time by cause of ESRD. On KaplanMeier estimates, differences in longitudinal survival were determined by the log-rank test, while the Gray test was used to measure differences in cumulative mortality. A Cox proportional hazards model was constructed to examine independent predictors of OS. Data analysis was performed using JMP Pro v.11.1 statistical software (SAS Institute, Cary, NC, USA) and R version 3.3.0 (R Project for Statistical Computing, Vienna, Austria). The cmprsk package in R was used to plot cumulative mortality, while the crr-addson add-on package was used to compute a regression analysis [21] . For the construction of these models, a highperformance computing cluster was utilized. In transplant recipients, RM-ESRD and OKC-ESRD patients were compared using propensity score matching to account for unmeasured and measured confounders with the MatchIt package [22] . Statistical significance was determined as P 0.05.
R E S U L T S
Patient characteristics and overall outcomes by cause of ESRD
Between 1983 to 2007, 1 374 175 patients with a known cause of ESRD were identified in the USRDS (Table 1) . Of these patients, 228 984 (16.7%) received a transplant, of whom a total of 501 (0.2%) were RM-ESRD, whereas 228 483 (99.8%) were As expected, ESRD patients who received a transplant exhibited improved OS compared with nontransplant recipients (P < 0.0001) ( Figure 1A) . With regard to nontransplant recipients, the median survival was 2.7 years and 1.7 years for patients with OKC-ESRD and RM-ESRD (P < 0.0001), respectively. These patients had a 5-year survival of 28.3% for patients with OKC-ESRD versus 20.3% for RM-ESRD. For transplant recipients, the median survival was 17.5 versus 15.3 years for patients with OKC-ESRD and RM-ESRD (P < 0.0001), respectively. However, regardless of transplant recipient status, patients with RM-ESRD had poorer OS than those with OKC-ESRD (P < 0.0001). A competing risk analysis was constructed to assess for either CSM or NCSM by primary cause of ESRD ( Figure 1B) . For both RM-ESRD and OKC-ESRD patients, NCSM was similar (P ¼ 0.27), while CSM was greater for RM-ESRD patients compared with those with OKC-ESRD (P < 0.0001). The 5-and 10-year cancer-specific mortalities were 0.5 versus 3.0% and 1.5 versus 9.3% for OKC-ESRD and RM-ESRD patients, respectively. For all causes of ESRD, NCSM was significantly greater than CSM.
Waiting duration disparities and contribution to OS
On evaluation of waiting duration, transplant recipients with RM-ESRD had longer waiting durations and were older than those with OKC-ESRD (age 44.1 versus 40.6 years, waiting duration 2.68 versus 2.05 years; P < 0.0001). When stratified by donor type, RM-ESRD patients had longer waiting durations than OKC-ESRD patients for both types of donors ( Figure 2A 
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In patients with RM-ESRD, early transplant recipients had a longer median OS after initiation of transplant compared with late transplant recipients (17.4 versus 8.99 years; P < 0.0001) ( Figure 2B) . Similarly, early RM-ESRD transplant recipients had improved 5-year survivals (79.6 versus 72.2%; P < 0.0001) compared with late RM-ESRD transplant recipients. Upon analysis of clinical characteristics, RM-ESRD early transplant recipients were found to be younger than late transplant recipients (40.9 versus 45.7 years; P ¼ 0.014) and more likely to receive a living donor transplant (61.6 versus 31.7%; P < 0.0001) (Supplementary data, Table S1 ).
A Cox proportional hazards model was constructed to assess for predictors of OS (Table 2 ). Male gender, increasing age, non-white race and cadaveric donor source were all found to be independent predictors of worse survival (P < 0.001). When adjusting for demographic variables, the status of RM-ESRD was not an independent predictor of outcome survival {hazard ratio [HR] 1.145 [95% confidence interval (CI) 1.006-1.321], P ¼ 0.070}. Transplant waiting duration was found to be a meaningful predictor of survival, as late transplant recipients were associated with worse outcome [HR 1.313 (95% CI 1.294-1.333), P < 0.001).
In a competing risk analysis of only RM-ESRD patients by transplant waiting duration, CSM was similar between early and late RM-ESRD transplant recipients (P ¼ 0.33) ( Figure 3A) . However, late transplant recipients exhibited a higher NCSM compared with early RM-ESRD transplant recipients (P ¼ 0.018). Of RM-ESRD patients, the 10-year NCSM was 19.1 versus 24% for early and late transplant recipients, respectively.
A Fine-Gray competing risks regression analysis was performed for both CSM and NCSM (Table 3) . For both causes of mortality, increasing age and male gender were associated with poorer survival (P < 0.001). On NCSM, a late transplant [HR 1.29 (95% CI 1.271-1.310), P < 0.001] was associated with poorer outcomes, while a living donor had improved outcomes We examined survival outcomes after the receipt of transplantation by waiting duration and found that RM-ESRD and OKC-ESRD transplant recipients exhibited similar OS after receiving an early transplant (P ¼ 0.97) ( Figure 3B ). These observations remained consistent even after propensity score matching (Supplementary data, Figure S1 ).
D I S C U S S I O N
Due to the national shortage of donor kidneys, there is an imperative need to select for appropriate transplant candidates [12] . Transplant recipients who are immunosuppressed have a significantly higher risk for a variety of malignancies, perhaps due to loss of normal immune surveillance eliminating transformed cells [23] . For transplant recipients with a prior malignancy, the impact of immunosuppression on cancer recurrence becomes a real concern [24] . For renal transplant recipients with a prior malignancy, these concerns have led to a delay in both enrollment on the transplant wait list and in the receipt of an organ, ultimately resulting in a longer duration on dialysis.
In our analysis of population data, we observed a longer waiting duration imposed on RM-ESRD candidates compared with OKC-ESRD candidates (2.4 versus 1.3 years) and thus a higher proportion of those receiving a late transplant (60.8 versus 34.8%). These observations are consistent with previous recommendations that deter early transplantation in those with a history of malignancy. For those with a prior history of renal malignancy, most guidelines recommend a recurrence-free period of at least 2 years before proceeding with transplantation, while those with aggressive tumors or symptomatic presentation may require a period of observation of at least 5 years [13] [14] [15] .
Due to the poor survival outcomes of remaining on dialysis [3] , many patients who cannot receive an early transplant may accumulate significant comorbidities, such as cardiovascular failure, that preclude future transplantation candidacy [13] . Perhaps as a result of the significant delay due to a mandatory wait duration, we observed that RM-ESRD patients were less likely than OKC-ESRD patients to ultimately receive a renal transplant (7.4 versus 16.7%). For those RM-ESRD patients who did proceed to transplant, survival was noted to be slightly worse than for OKC-ESRD patients; however, when controlling for other prognostic factors, OS was no longer influenced by cause of ESRD [HR 1.145 (95% CI 1.006-1.321), P ¼ 0.07]. Upon examination of cause-specific mortality, we found that RM-ESRD patients had a slightly higher CSM (5-year CSM 3 versus 0.5%; P < 0.0001) than OKC-ESRD patients, as expected, however, NCSM remained similar (P ¼ 0.27).
For potential transplant recipients with prior malignancy, waiting duration recommendations have varied, ranging from 2 to 5 years depending on the type of malignancy. These guidelines have been formulated with knowledge of recurrence rates prior to transplantation and are precautionary to minimize oncologic risk. For RCC, since 85% of recurrences manifest within the first 2 years, there are significant concerns for allocating an organ to an individual who may not be cancer-free without this period of observation. However, our data suggest that these existing guidelines may have a detrimental effect on patient outcome, which may signify the need for a paradigm shift in the assessment of suitable transplant candidates with a prior history of renal malignancy. In our study we observed that 198 (39.5%) RM-ESRD patients received an early transplant without this period of observation, yet their survival was significantly better than those with late transplants (median survival 17.4 versus 9.0 years; P ¼ 0.0006). While individualized assessment for each candidate is necessary, our data suggest that the waiting duration does not alter CSM posttransplantation [HR 0.989 (95% CI 0.929-1.05), P ¼ 0.72] but remains an important contributor to NCSM [HR 1.29 (95% CI 1.271-1.31), P < 0.001]. These observations are consistent with those reported in a Norwegian registry study that evaluated a pre-transplant cancer diagnosis. In this study, while CSM was slightly higher in those with a prior malignancy diagnosis, waiting duration prior to transplantation was not associated with recurrent cancer mortality [25] . Collectively, our study suggests current recommendations may result in higher NCSM and thus poorer OS. These concerns are further supported by the observation that RM-ESRD patients who received an early transplant demonstrated similar OS to early transplant recipients from the OKC-ESRD group, which remained consistent after propensity score matching.
The strengths of this study include inclusion of the entire US ESRD population with detailed follow-up and demographic information. Inherent to any large retrospective database, granular clinical information was not available, such as significant comorbidities, cancer grade and stage and treatment type. Limited information is available for RM-ESRD patients, including their date of cancer diagnosis relative to progression to ESRD. However, since surgical loss of renal function after surgery is a major complication from treatment, and many of these patients likely had a cancer diagnosis and surgery relatively close to the time of ESRD diagnosis.
In summary, patients with RM-ESRD often are unable to receive a transplant and when they do it is significantly delayed compared with other transplant recipients. Current guidelines recommend a waiting duration of at least 2 years before proceeding with transplantation, however, with this strategy, those with renal malignancy may have worse outcome, perhaps due to a greater time on dialysis. Those who receive an early transplant appear to have better survival than late recipients, without an increase in CSM. Our data suggest reconsideration of the current guidelines in order to improve outcome in individuals with RM-ESRD.
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